Literature DB >> 2930063

Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis.

R M Hoffman1, J H Dauber, R M Rogers.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the accumulation of lipoproteinaceous material in the alveolar space. Alveolar macrophages (AM) in this disease have been noted in the past to have abnormally decreased function. It is not known whether these abnormalities are reversible with treatment of the disease. In this study, the effect of therapeutic whole lung lavage (WLL) on AM migration in four patients with PAP was determined. Standard segmental bronchoalveolar lavage (BAL) was performed 1 day before and 6 days after WLL. AM recovered by BAL were assayed for migratory response to N-formyl-methionyl phenylalanine (FMP) and endotoxin-activated human serum (EAHS). As expected, migration toward both stimuli was decreased before WLL compared to a group of normal controls. After WLL, AM migration toward both stimuli was not only greater than before the WLL but also was greater than normal. In one patient, serial BAL over a period of 18 months showed a marked decline in AM migration coincident with a clinical relapse of the disease. Thus, the defect in AM function found in PAP is reversible with WLL but can recur if clinical remission is not sustained.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930063     DOI: 10.1164/ajrccm/139.4.1030

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  6 in total

Review 1.  Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.

Authors:  P L Shah; D Hansell; P R Lawson; K B Reid; C Morgan
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Dipalmitoylphosphatidylcholine modulates inflammatory functions of monocytic cells independently of mitogen activated protein kinases.

Authors:  A Tonks; R H Morris; A J Price; A W Thomas; K P Jones; S K Jackson
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Surfactant protein D. Increased accumulation in silica-induced pulmonary lipoproteinosis.

Authors:  E Crouch; A Persson; D Chang; D Parghi
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

4.  Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.

Authors:  Spyros A Papiris; Panagiotis Tsirigotis; Likurgos Kolilekas; Georgia Papadaki; Andriana I Papaioannou; Christina Triantafillidou; Anastasia Papaporfyriou; Anna Karakatsani; Konstantinos Kagouridis; Matthias Griese; Effrosyni D Manali
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

Review 5.  Metabolic Functions of the Lung, Disorders and Associated Pathologies.

Authors:  Alcibey Alvarado; Isabel Arce
Journal:  J Clin Med Res       Date:  2016-08-30

6.  Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody.

Authors:  Toru Arai; Takahiko Kasai; Kazunori Shimizu; Kunimitsu Kawahara; Kanako Katayama; Chikatoshi Sugimoto; Masaki Hirose; Hiroyuki Okamoto; Kazunobu Tachibana; Masanori Akira; Yoshikazu Inoue
Journal:  Intern Med       Date:  2020-06-30       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.